Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Enzo Biochem (ENZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 419,850
  • Shares Outstanding, K 46,290
  • Annual Sales, $ 102,770 K
  • Annual Income, $ 45,290 K
  • 36-Month Beta 1.34
  • Price/Sales 4.03
  • Price/Cash Flow 0.00
  • Price/Book 4.72

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.55 +6.32%
on 04/27/17
9.68 -6.10%
on 05/12/17
+0.29 (+3.30%)
since 04/24/17
3-Month
6.42 +41.59%
on 02/28/17
9.68 -6.10%
on 05/12/17
+2.43 (+36.49%)
since 02/24/17
52-Week
4.88 +86.27%
on 09/30/16
9.68 -6.10%
on 05/12/17
+2.75 (+43.38%)
since 05/24/16

Most Recent Stories

More News
Merrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde

Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 22 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents. The company had reported a loss...

ENZ : 9.06 (-0.11%)
CATB : 1.36 (+0.73%)
SHPG : 185.08 (+0.05%)
MACK : 3.44 (-2.82%)
Orexigen Posts Wider-than-Expected Loss in Q1, Sales Up Y/Y

Orexigen Therapeutics, Inc.'s (OREX) loss of $4.67 per share in the first quarter of 2017 was significantly wider than the Zacks Consensus Estimate of a loss of $2.60 and the year-ago loss of $1.54.

ENZ : 9.06 (-0.11%)
OREX : 2.87 (-2.71%)
CATB : 1.36 (+0.73%)
AGTC : 5.32 (-0.56%)
Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y

Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.25 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.22 and the year-ago loss of $1.21.

ENZ : 9.06 (-0.11%)
MDCO : 40.00 (-2.32%)
ALNY : 70.55 (-5.77%)
SNY : 49.14 (+0.14%)
After Gilead Earnings, Buy These Biotech Stocks

Shares of Gilead Sciences (GILD) are down about 2.6% in midday trading Wednesday after the biotech giant's first-quarter sales fell short of analyst estimates yesterday, leaving investors disappointed....

ENZ : 9.06 (-0.11%)
GILD : 64.36 (-0.51%)
REGN : 457.80 (-0.77%)
Enzo Biochem's Clinical Laboratory Named an In-Network Provider to the Fourth Largest National Insurer

Enzo Biochem, Inc. (NYSE:ENZ) announced today that its Enzo Clinical Laboratory subsidiary, a full-service clinical laboratory with a specialty in women's health, today reached an agreement...

ENZ : 9.06 (-0.11%)
Illumina (ILMN) Launches VeriSeq NIPT Solution in Europe

Illumina, Inc. (ILMN) recently announced the launch of a solution pertaining to its noninvasive prenatal testing (NIPT) range in Europe.

ENZ : 9.06 (-0.11%)
HSKA : 100.35 (+2.34%)
ILMN : 174.52 (-0.11%)
GLPG : 83.83 (-1.21%)
Amedisys (AMED) Poised on Strong Home Health, Risks Remain

On Apr 04, we issued an updated research report on renowned home health and hospice services provider, Amedisys Inc. (AMED).

ENZ : 9.06 (-0.11%)
HSKA : 100.35 (+2.34%)
AMED : 58.92 (+0.46%)
GLPG : 83.83 (-1.21%)
QIAGEN Releases Favorable GeneReader Results, Expands in NGS

QIAGEN N.V. (QGEN) recently has validated its GeneReader NGS System and published five new independent studies.

ENZ : 9.06 (-0.11%)
HSKA : 100.35 (+2.34%)
QGEN : 32.64 (-0.34%)
GLPG : 83.83 (-1.21%)
Enzo Biochem Stock: 3 Reasons Why ENZ Is a Top Choice for Momentum Investors

Let's focus on Enzo Biochem, Inc. (ENZ) as this momentum stock is looking especially impressive right now.

ENZ : 9.06 (-0.11%)
Earnings Estimates Moving Higher for Enzo Biochem (ENZ): Time to Buy?

Enzo Biochem (ENZ) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

ENZ : 9.06 (-0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo...

See More

Support & Resistance

2nd Resistance Point 9.28
1st Resistance Point 9.18
Last Price 9.06
1st Support Level 8.95
2nd Support Level 8.82

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.